Imaging biomarkers for better decisions

From study design to final reporting, Bioxydyn delivers repeatable MRI biomarkers that reveal tissue function, physiology and change. Our operational excellence and metrology help you compare results across sites, scanners and timepoints.

Statistics

We're Bioxydyn - delivering quantitative MR biomarkers for pharmaceutical, biotech and academic studies. We combine scientifically leading methods with robust multi-centre study management and transparent analysis, turning complex images into repeatable measurements that support confident decisions.

0
Years of delivery

Founded in 2009, Bioxydyn has been delivering commercial multi-centre clinical trials since.

0
Continents

Sites trained across North America, Europe, Asia, Australia, South America and Africa.

0
Proprietary Platform

VoxelFlow supports your clinical trial end-to-end, delivering reliable, repeatable and auditable outputs. It is compliant with FDA 21 CFR Part 11

Asthma Interstitial lung disease (ILD) Generic oncology / tumour hypoxia Rheumatoid arthritis Multiple sclerosis Neuro-oncology Liver / hepatobiliary system
Heart / cardiovascular system
Cystic fibrosis Primary ciliary dyskinesia (PCD) Oropharyngeal cancer Osteoarthritis Neurodevelopmental disorders Drug-induced liver injury (DILI) Kidneys / renal system Tumours (multi-organ)
COPD Pulmonary embolism Liver cancer Nephritis Dementia Drug-induced lung injury Brain / central nervous system
Blood vessels / microvasculature
Pulmonary hypertension Lung cancer Renal cell carcinoma Lupus nephritis Alzheimer's disease Lungs / respiratory system Joints / musculoskeletal system

Our Work

Disease areas and services supporting quantitative MRI biomarkers across clinical trials.

view all
Respiratory

Disease area

Quantitative MRI for ventilation and perfusion across respiratory diseases and trial endpoints.

  • Oxygen-enhanced MRI (OE-MRI) ventilation biomarkers
  • DCE-MRI perfusion and microvascular measures
  • Motion-based ventilation imaging without gases
  • Support for hyperpolarised 129Xe studies
  • Validated methods across vendors and sites
Oncology

Disease area

Functional MRI biomarkers to characterise tumour physiology and therapy response.

  • Oxygen-enhanced MRI (OE-MRI) for tumour hypoxia
  • DCE-MRI biomarkers of angiogenesis and perfusion
  • Diffusion MRI (ADC) for early response detection
  • Cross-site protocol standardisation and QA
  • Auditable analysis and reporting with VoxelFlow
Inflammation

Disease area

Imaging biomarkers for inflammatory joint and renal disease with sensitive pharmacodynamic readouts.

  • DCE-MRI Ktrans biomarkers of microvascular function
  • Joint imaging in rheumatoid arthritis and osteoarthritis
  • Renal imaging biomarkers including ASL, T1, T2, ADC
  • Hypoxia and pH imaging methods (BOLD, OE-MRI, CEST)
  • Sensitive, repeatable measurements with small cohorts
Neuroimaging

Disease area

Quantitative MRI and AI-enabled analysis to stratify neurological conditions.

  • Atrophy and diffusion metrics for neurodegeneration
  • DCE-MRI for subtle blood-brain barrier dysfunction
  • Arterial spin labelling (ASL) perfusion methods
  • MR spectroscopy and relaxometry
  • AI stratification with Queen Square Analytics
Liver imaging

Disease area

Gadoxetate DCE-MRI biomarkers of transporter function and hepatobiliary physiology.

  • Gadoxetate DCE-MRI for uptake and efflux kinetics
  • Relaxometry (T1, T2, T2*) for tissue status
  • TRISTAN project leadership and validation
  • FDA biomarker qualification program acceptance
  • Study design, QC, analysis, and reporting
Imaging Biomarkers in Drug Safety Assessment

Disease area

Safety-focused imaging biomarkers with rigorous cross-site standardisation and transparent analysis.

  • Liver and lung toxicity assays
  • Metrology for multi-centre comparability
MR Spectroscopy

Disease area

Spectroscopy protocols and analysis to quantify metabolic and biochemical change.

  • Multi-site harmonisation
  • Auditable processing workflows
Publications

Service

Peer-reviewed evidence demonstrating repeatability and clinical relevance.

  • Large publication footprint
  • Study interpretation support
Software Development Services

Service

Custom imaging software, automation, and analytics built for regulated studies.

  • High-performance pipelines
  • Secure and auditable tooling
Trial Design and Imaging Strategy Services

Service

Trial-ready imaging strategy from protocol design to endpoint selection.

  • Acquisition standardisation
  • Biomarker feasibility planning
VoxelFlow

Service

Validated analysis and study management platform for quantitative MRI.

  • End-to-end QC and audit trails
  • Transparent biomarker calculation
Imaging Data Management

Service

Secure data intake, curation, and traceable imaging datasets.

  • Multi-centre data workflows
  • Compliance-ready archiving
Imaging Site Support

Service

Site qualification, training, and ongoing acquisition support.

  • Remote or on-site setup
  • Quality feedback loops
MR Protocol development & harmonisation

Service

Harmonised MR protocols designed for cross-site consistency.

  • Vendor-agnostic sequences
  • Robust calibration guidance
Quality & Compliance

Service

GxP-aligned processes for reliable, defensible imaging biomarkers.

  • SOP-driven operations
  • Auditable reporting
Website built by Bioxydyn. We can build software for you - get in touch.